Targeted Medical Pharma Reports Initial Results from a Clinical Observation of Medical Foods for Children and Adults with Autistic Spectrum Disorder Symptoms

Addressing the Nutrient Deficiencies Associated with Autism Spectrum Disorders for both Children and Adults

Los Angeles, CA, December 23, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced additional preliminary findings from an investigator initiated clinical observation of amino acid based medical foods to address specific nutrient deficiencies in children and young adults with autism spectrum disease (ASD) symptoms.

34 subjects including 29 children and 5 young adults ages seven to twenty-one who were diagnosed with ASD or suffering from related symptoms including explosive behavior, social isolation, and mood disorder were treated with an amino acid based formulation for one to several months. The investigators reported that 33 of the subjects were initial responders and demonstrated significant improvement with regards to decreased disruptive outbursts, improved socialization, improved mood and reduction in drug dose. Patients with explosive outbursts improved an average of 83 percent compared to baseline. The five adults reported improved mood and reduction of anxiety from 50% to 90% and in one case a 100% reduction in symptoms of mania. The investigators caution that the sample for adults is small and that an additional four cases were lost to follow-up.

“The formulations used in the investigation are milligram amounts of precursors to neurotransmitters using a proprietary technology protected by several patents.” said William Shell, M.D., CEO and Chief Science Officer of Targeted Medical Pharma.  “Autism affects the way patients metabolize certain nutrients and we believe that our medical food technology is a safe and effective way to increase amino acid and neurotransmitter levels for both children and adults. A key target of the formulation is the glutamine/glutamate access which is known to be disrupted in autistic spectrum disease patients. Measurement of amino acid concentrations in plasma and cerebrospinal fluid indicate a significant alteration of amino acid concentrations demonstrating a specific need for nutritional management of the amino acid concentrations.”

“The current pharmacologic treatments available for this patient population do not address the specific nutrient deficiencies, and are associated with a host of negative side effects,” said David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma. “The initial results from this observation show that the symptoms of Autism in children and young adults can potentially be improved by addressing the specific nutritional deficiencies of the disease. The amino acids used in the study are considered generally recognized as safe(GRAS) and no significant side effects were observed.”

A double-blind randomized placebo controlled trial will be initiated shortly.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma Senior Management Buys Stock and Converts Loans to Equity

17,780 Shares Purchased on the Open Market and $1,000,000 Loan Converted to Stock

Los Angeles, CA, December 18, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that senior management has purchased 17,780 shares of the Company’s stock in the open market during the fourth quarter of 2013. In addition, Company CEO William Shell, M.D. also converted $1,000,000 in loans, which were made to the company in 2011 to fund production growth, into TRGM common stock.

“The purchase of shares and conversion of loans by members of senior management demonstrates our strong confidence in the company and reflects our commitment to executing our business plan and delivering shareholder value.” Said David Silver M.D., President and Chief Operating Officer at Targeted Medical Pharma. “We have worked very hard to improve revenue and manage operating costs and today’s announcement reflects our growing confidence in Targeted Medical and the medical foods sector.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma to Present at 6th Annual LD Micro Growth Conference

Los Angeles, December 4, 2013 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that members of its executive team are scheduled to present and conduct one-on-one meetings at the LD Micro Growth Conference on December 5, 2012 at 1:30 p.m. Pacific Time. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for autistic spectrum disorders and for the oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.